Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 21, 2016PLoS ONEOpen Access

Sodium-Glucose Cotransporter 2 Inhibitor and a Low Carbohydrate Diet Affect Gluconeogenesis and Glycogen Content Differently in the Kidney and the Liver of Non-Diabetic Mice

View Full Paper
Ask AI
Bookmark
Share

Authors

KAKuralay AtageldiyevaYFYukihiro FujitaTYTsuyoshi Yanagimachi

Discussion

Loading...

Member takes

Overview

Animal study demonstrates divergent hepatic and renal metabolic effects of SGLT2 inhibition and a low-carbohydrate diet in non-diabetic mice, indicating distinct tissue-specific adaptations.

Key Points

  • To compare the metabolic impacts of a low-carbohydrate diet versus SGLT2 inhibition on insulin sensitivity, fat accumulation, gluconeogenesis, and glycogen stores in the liver and kidney of non-diabetic mice.
  • Assigned non-diabetic mice to an 8-week ad-libitum feeding protocol of either a low-carbohydrate diet (LCHD) or a normal-carbohydrate diet (NCHD), with or without the SGLT2 inhibitor ipragliflozin.
  • Evaluated metabolic parameters, oral glucose tolerance, gene expression of gluconeogenic and lipid metabolic enzymes, and glycogen content in kidney and liver tissues.
  • SGLT2 inhibitor treatment improved oral glucose tolerance, upregulated renal gluconeogenic enzyme expression, depleted liver glycogen, and stimulated renal glycogen accumulation.
  • LCHD increased body weight, epididymal fat mass, and insulin resistance while selectively upregulating gluconeogenic gene expression in the liver rather than the kidney.

Cite This Study

Atageldiyeva et al. (2016) studied this question.

synapsesocial.com/papers/6a736b1983fe59cdbfc1e78ehttps://doi.org/10.1371/journal.pone.0157672
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) plus glucagon‐like peptide type 1 receptor combination is more effective than SGLT2i plus dipeptidyl peptidase‐4 inhibitor combination in treating obese mice metabolic dysfunction‐associated steatotic liver disease (MASLD)2024 · 6 citations
  2. 2Mechanism of Increased LDL (Low-Density Lipoprotein) and Decreased Triglycerides With SGLT2 (Sodium-Glucose Cotransporter 2) Inhibition2018 · 173 citations
  3. 3Metabolic effects of SGLT2i and metformin on 3-hydroxybutyric acid and lactate in db/db mice2024 · 6 citations
  4. 4Effects of SGLT2 Ablation or Inhibition on Corticosterone Secretion in High-Fat-Fed Mice: Exploring a Nexus with Cytokine Levels2024 · 1 citations
  5. 5Sodium-glucose co-transporter 2 Inhibitors Act Independently of SGLT2 to Confer Benefit for Heart Failure with Reduced Ejection Fraction in Mice2024 · 6 citations